- Home
- BWMX vs TRVI Comparison
BWMX vs TRVI Comparison
Compare BWMX & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWMX
- TRVI
- Stock Information
- Founded
- BWMX 1995
- TRVI 2011
- Country
- BWMX Mexico
- TRVI United States
- Employees
- BWMX N/A
- TRVI N/A
- Industry
- BWMX Catalog/Specialty Distribution
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- BWMX Consumer Discretionary
- TRVI Health Care
- Exchange
- BWMX Nasdaq
- TRVI Nasdaq
- Market Cap
- BWMX 447.8M
- TRVI 383.4M
- IPO Year
- BWMX N/A
- TRVI 2019
- Fundamental
- Price
- BWMX $11.40
- TRVI $5.97
- Analyst Decision
- BWMX Strong Buy
- TRVI Strong Buy
- Analyst Count
- BWMX 1
- TRVI 8
- Target Price
- BWMX $22.50
- TRVI $17.56
- AVG Volume (30 Days)
- BWMX 16.3K
- TRVI 4.5M
- Earning Date
- BWMX 04-24-2025
- TRVI 03-18-2025
- Dividend Yield
- BWMX 12.10%
- TRVI N/A
- EPS Growth
- BWMX N/A
- TRVI N/A
- EPS
- BWMX 0.92
- TRVI N/A
- Revenue
- BWMX $676,704,288.00
- TRVI N/A
- Revenue This Year
- BWMX $8.79
- TRVI N/A
- Revenue Next Year
- BWMX $6.14
- TRVI N/A
- P/E Ratio
- BWMX $12.42
- TRVI N/A
- Revenue Growth
- BWMX 8.39
- TRVI N/A
- 52 Week Low
- BWMX $10.05
- TRVI $2.30
- 52 Week High
- BWMX $20.36
- TRVI $7.39
- Technical
- Relative Strength Index (RSI)
- BWMX 48.91
- TRVI 53.50
- Support Level
- BWMX $11.47
- TRVI $6.22
- Resistance Level
- BWMX $12.00
- TRVI $6.68
- Average True Range (ATR)
- BWMX 0.42
- TRVI 0.35
- MACD
- BWMX 0.01
- TRVI -0.10
- Stochastic Oscillator
- BWMX 32.25
- TRVI 2.12
About BWMX Betterware de Mexico S.A.P.I. de C.V.
Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided into different categories based on the type of products it sells and includes, kitchen and food preservation, home solutions, bathroom, laundry & cleaning, tech and mobility, and bedroom and wellness products. The JAFRA's segment is divided into fragrance, color, skincare, and toiletries products. The company generates a majority of its revenue from the Beauty and personal care (B&PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.